Faculty of Pharmacy, Toulouse III university, France; Medical biochemistry laboratory, CHU Toulouse, France.
Medical biochemistry laboratory, CHU Toulouse, France; Faculty of Medicine, Toulouse III university, France.
Infect Dis Now. 2024 Mar;54(2):104860. doi: 10.1016/j.idnow.2024.104860. Epub 2024 Feb 1.
The COVID-19 epidemic still calls for anticipation aimed at preventing the overloading of critical care services. With this in mind, the predictive value of easily accessible biomarkers is to be assessed.
Secretion of calprotectin is stimulated during an inflammatory process, especially in the cytokine storm. We tried to determine whether early plasma concentration of calprotectin in patients with primary SARS-CoV-2 infection could predict an adverse outcome in cases of COVID-19.
We included 308 patients with a primary diagnosis of SARS-CoV-2 confirmed by PCR. Heparinized tube samples, collected within the first 24 h of hospitalization, were used for biomarker assays, in which plasma calprotectin was included. Data from the patients' medical records and severity groups established subsequent to diagnosis at the end of hospitalization were collected.
Early plasma calprotectin concentration is significantly associated with progression to a severe form of COVID-19 in patients with primary infection (Relative Risk: 2.2 [1.6-2.7]). In multivariate analysis, however, it does not appear to provide additional information compared to other parameters (age, GFR, CRP…).
Our study shows that while an early single blood test for calprotectin could help to predict the progression of a primary SARS-CoV-2 infection, it is not superior to the other parameters currently used in emergency medicine. However, it paves the way for future considerations, such as the interest of this biomarker for high-risk infected patients (immunocompromised individuals…). Finally, the usefulness of early serial measurements of plasma calprotectin to assess progression towards severity of COVID-19 requires further assessment.
COVID-19 疫情仍需要预测，以防止重症监护服务过载。考虑到这一点，需要评估易于获取的生物标志物的预测价值。
钙卫蛋白在炎症过程中被刺激分泌，特别是在细胞因子风暴中。我们试图确定原发性 SARS-CoV-2 感染患者早期血浆钙卫蛋白浓度是否可以预测 COVID-19 的不良结局。
我们纳入了 308 例经 PCR 确诊的原发性 SARS-CoV-2 感染患者。在住院的头 24 小时内采集肝素化管样本，用于生物标志物检测，其中包括血浆钙卫蛋白。收集患者病历数据和住院结束时根据病情严重程度分组的数据。
早期血浆钙卫蛋白浓度与原发性感染患者进展为严重 COVID-19 显著相关（相对风险：2.2 [1.6-2.7]）。然而，在多变量分析中，与其他参数（年龄、GFR、CRP 等）相比，它似乎没有提供额外的信息。
我们的研究表明，虽然早期单次血液钙卫蛋白检测有助于预测原发性 SARS-CoV-2 感染的进展，但它并不优于急诊医学中目前使用的其他参数。然而，它为未来的考虑铺平了道路，例如该生物标志物对高危感染患者（免疫功能低下者等）的意义。最后，需要进一步评估早期连续测量血浆钙卫蛋白评估 COVID-19 严重程度进展的作用。
